Recent Updates — OTLK
Outlook Therapeutics received a notice from Nasdaq on September 25, 2026, indicating its common stock closed below $1.00 per share for the last 30 consecutive business days, violating minimum bid price requirements under Listing Rule 5550(a)(2). The company has until March 24, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. Failure to comply may result in delisting, though an additional 180-day cure period is available if other listing standards are met. The company intends to evaluate options to resolve the deficiency. Outlook Therapeutics operates in the biotechnology industry, developing therapies for cancer and inflammatory diseases.
Outlook Therapeutics announced that CFO Lawrence A. Kenyon mutually agreed to cease serving as Chief Financial Officer, Treasurer, Corporate Secretary, and Board member effective September 1, 2026. The Board appointed Kevin Lundquist as the new CFO, Treasurer, principal financial officer, and principal accounting officer on the same date. Lundquist receives a $450,000 annual base salary, a target bonus of 50% of base, and a special grant of 500,000 stock options. Kenyon will remain in a non-executive role through September 30, 2026, with severance including twelve months' salary, full target bonus acceleration, and COBRA coverage. The Board size is reduced to eight directors upon Kenyon's departure. Outlook Therapeutics operates in the biotechnology industry.
On August 12, 2026, Outlook Therapeutics entered into an underwriting agreement for a public offering of 55,555,556 shares of common stock and accompanying warrants to purchase up to the same number of shares. The combined public offering price is $0.99 per share and warrant. Gross proceeds are estimated at approximately $55.0 million before deducting underwriting discounts and commissions. Each warrant carries an initial exercise price of $1.10 and expires five years from issuance. The underwriters exercised their option to purchase additional warrants for 8,333,333 shares. Key insiders, including CEO Robert Jahr and CFO Lawrence Kenyon, along with largest stockholder GMS Ventures, purchased shares in the offering. Outlook Therapeutics operates in the biotechnology industry.
Outlook Therapeutics reported preliminary cash and cash equivalents of approximately $11.2 million as of June 30, 2026. The company announced that the FDA approved LYTENAVA (bevacizumab-vikg) for neovascular age-related macular degeneration on July 24, 2026, and filed amended risk factors reflecting this approval. Additionally, Outlook terminated its At The Market Offering Agreement with H.C. Wainwright & Co., effective August 10, 2026, though the underlying sales agreement remains in force. The company operates in the biopharmaceutical industry, developing and commercializing treatments for ophthalmic diseases.